UB Paderborn / Katalog / Suche / in CDI

Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection

Liver international, 2017-01, Vol.37 (1), p.5-18

2017

Link zum Volltext

Verfügbarkeit prüfen

HEPLA: A multicenter study on demographic and disease characteristics of patients with hepatitis C in Latin America

Annals of hepatology, 2020-03, Vol.19 (2), p.161-165

2020

Link zum Volltext

Verfügbarkeit prüfen

Effect of different interferonα2 preparations on IP10 and ET-1 release from human lung cells

PloS one, 2012-10, Vol.7 (10), p.e46779-e46779

2012

Link zum Volltext

Verfügbarkeit prüfen

SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHeSYS study

Annals of hepatology, 2014-03, Vol.13 (2), p.303-304

2014

Link zum Volltext

Verfügbarkeit prüfen

High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials

Hepatology (Baltimore, Md.), 2012-12, Vol.56 (6), p.2039-2050

2012

Link zum Volltext

Verfügbarkeit prüfen

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial

Annals of hepatology, 2012-01, Vol.11 (1), p.52-61

2012

Link zum Volltext

Verfügbarkeit prüfen

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

Journal of hepatology, 2020-03, Vol.72 (3), p.431-440

2020

Link zum Volltext

Verfügbarkeit prüfen

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts

Journal of viral hepatitis, 2022-12, Vol.29 (12), p.1050-1061

2022

Link zum Volltext

Verfügbarkeit prüfen

AML-119 The Impact of Post-Remission Granulocyte Colony-Stimulating Factor (G-CSF) Use (G-CSFu) in the Phase 3 Studies of Venetoclax (Ven) Combination Treatments in Patients (Pts) With Newly Diagnosed Acute Myeloid Leukemia (AML)

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S214

2022

Link zum Volltext

Verfügbarkeit prüfen

Poster: AML-119 The Impact of Post-Remission Granulocyte Colony-Stimulating Factor (G-CSF) Use (G-CSFu) in the Phase 3 Studies of Venetoclax (Ven) Combination Treatments in Patients (Pts) With Newly Diagnosed Acute Myeloid Leukemia (AML)

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S124

2022

Link zum Volltext

Verfügbarkeit prüfen

Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin

Journal of hepatology, 2012-06, Vol.56 (6), p.1276-1282

2012

Link zum Volltext

Verfügbarkeit prüfen

Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis

Journal of hepatology, 2017-10, Vol.67 (4), p.700-707

2017

Link zum Volltext

Verfügbarkeit prüfen

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin

Liver international, 2018-09, Vol.38 (9), p.1571-1575

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts

Advances in therapy, 2021-06, Vol.38 (6), p.3409-3426

2021

Link zum Volltext

Verfügbarkeit prüfen

PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study

Journal of hepatology, 2019-04, Vol.70 (1), p.e110-e110

2019

Link zum Volltext

Verfügbarkeit prüfen

Serological markers of hepatitis A, B and C viruses in rural communities of the semiarid Brazilian northeast

The Brazilian journal of infectious diseases, 2006-10, Vol.10 (5), p.317-321

2006

Link zum Volltext

Verfügbarkeit prüfen

Response to Cytoplasmic rods and rings in ribavirin and Cytoplasmic rods and rings in mycophenolic acid treatment

Liver international, 2017-11, Vol.37 (11), p.1743-1744

2017

Link zum Volltext

Verfügbarkeit prüfen

Sustained Virologic Response Rate of 96% in HCV Genotype 1a-Infected Patients Treated With Ombitasvir/Paritaprevir/r and Dasabuvir With Ribavirin: 2048

The American journal of gastroenterology, 2015-10, Vol.110, p.S862

2015

Link zum Volltext

Verfügbarkeit prüfen

A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin

Liver international, 2014-11, Vol.34 (10), p.1550-1559

2014

Link zum Volltext

Verfügbarkeit prüfen

Su1422 Efficacy and Safety of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir Without Ribavirin in Patients with HCV Genotype 1b With or Without Compensated Cirrhosis: Pooled Analysis Across 5 Clinical Trials

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S1095-S1095

2016

Link zum Volltext

Verfügbarkeit prüfen

Aspectos sociodemográficos da soroprevalência de marcadores do vírus da hepatite A no povoado de Cavunge, região do semi-árido do Estado da Bahia

Revista da Sociedade Brasileira de Medicina Tropical, 2006-02, Vol.39 (1), p.76-78, Article 76

2006

Link zum Volltext

Verfügbarkeit prüfen

IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study

SpringerPlus, 2016-11, Vol.5 (1), p.1990-1990, Article 1990

2016

Link zum Volltext

Verfügbarkeit prüfen

Effect of Different Interferon[alpha]2 Preparations on IP10 and ET-1 Release from Human Lung Cells

PloS one, 2012-10, Vol.7 (10), p.e46779

2012

Link zum Volltext

Verfügbarkeit prüfen

In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions

Liver international, 2014-08, Vol.34 (7), p.e217-e228

2014

Link zum Volltext

Verfügbarkeit prüfen

Pharmacoeconomics applied to chronic hepatitis C

The Brazilian journal of infectious diseases, 2006-02, Vol.10 (1), p.51-54

2006

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection

HEPLA: A multicenter study on demographic and disease characteristics of patients with hepatitis C in Latin America

Effect of different interferonα2 preparations on IP10 and ET-1 release from human lung cells

SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHeSYS study

High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts

AML-119 The Impact of Post-Remission Granulocyte Colony-Stimulating Factor (G-CSF) Use (G-CSFu) in the Phase 3 Studies of Venetoclax (Ven) Combination Treatments in Patients (Pts) With Newly Diagnosed Acute Myeloid Leukemia (AML)

Poster: AML-119 The Impact of Post-Remission Granulocyte Colony-Stimulating Factor (G-CSF) Use (G-CSFu) in the Phase 3 Studies of Venetoclax (Ven) Combination Treatments in Patients (Pts) With Newly Diagnosed Acute Myeloid Leukemia (AML)

Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin

Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts

PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study

Serological markers of hepatitis A, B and C viruses in rural communities of the semiarid Brazilian northeast

Response to Cytoplasmic rods and rings in ribavirin and Cytoplasmic rods and rings in mycophenolic acid treatment

Sustained Virologic Response Rate of 96% in HCV Genotype 1a-Infected Patients Treated With Ombitasvir/Paritaprevir/r and Dasabuvir With Ribavirin: 2048

A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin

Su1422 Efficacy and Safety of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir Without Ribavirin in Patients with HCV Genotype 1b With or Without Compensated Cirrhosis: Pooled Analysis Across 5 Clinical Trials

Aspectos sociodemográficos da soroprevalência de marcadores do vírus da hepatite A no povoado de Cavunge, região do semi-árido do Estado da Bahia

IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study

Effect of Different Interferon[alpha]2 Preparations on IP10 and ET-1 Release from Human Lung Cells

In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions

Pharmacoeconomics applied to chronic hepatitis C

Suchergebnisse filtern